Sequenom (Sequenom) Net Margin % : -21.54% (As of Jun. 2016)

View and export this data going back to 2000. Start your Free Trial

What is Sequenom Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Sequenom's Net Income for the three months ended in Jun. 2016 was $-6.3 Mil. Sequenom's Revenue for the three months ended in Jun. 2016 was $29.3 Mil. Therefore, Sequenom's net margin for the quarter that ended in Jun. 2016 was -21.54%.

The historical rank and industry rank for Sequenom's Net Margin % or its related term are showing as below:

SQNM's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -162.84
* Ranked among companies with meaningful Net Margin % only.

Sequenom Net Margin % Historical Data

The historical data trend for Sequenom's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom Net Margin % Chart

Sequenom Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Net Margin %

Get a 7-Day Free Trial

-132.60

-251.91

-89.84

0.67

-12.73

Sequenom Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Net Margin %	Get a 7-Day Free Trial															-27.51	-31.58	-43.73	-48.78	-21.54

Competitive Comparison of Sequenom's Net Margin %

For the Biotechnology subindustry, Sequenom's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sequenom's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sequenom's Net Margin % distribution charts can be found below:

* The bar in red indicates where Sequenom's Net Margin % falls into.

Sequenom Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Sequenom's Net Margin for the fiscal year that ended in Dec. 2015 is calculated as

Net Margin	=	Net Income (A: Dec. 2015 )	/	Revenue (A: Dec. 2015 )
	=	-16.331	/	128.282
	=	-12.73 %

Sequenom's Net Margin for the quarter that ended in Jun. 2016 is calculated as

Net Margin	=	Net Income (Q: Jun. 2016 )	/	Revenue (Q: Jun. 2016 )
	=	-6.307	/	29.287
	=	-21.54 %

Sequenom (NAS:SQNM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Sequenom Net Margin % Related Terms

Thank you for viewing the detailed overview of Sequenom's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sequenom (Sequenom) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sequenom.com

Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.

Executives

Richard A Lerner	director	THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler	director
Charles P Slacik	director	250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton	officer: Sr VP, GC & Secretary	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver	officer: SVP & CFO	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller	director	430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas	director
Goldman Myla Lai	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii	director, officer: Chairman, President & Sec	22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg	director, officer: EVP and Treasurer	P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis	director	REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch	officer: President & CEO	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121